ABDX - Ticker AI Digest

Abingdon Health Plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (ABDX) 1
ABDX 06:01
Abingdon Health Plc
Vesting and Award of Options under LTIP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 1
ABDX 06:01
Abingdon Health Plc
Vesting and Award of Options under LTIP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
ABDX 06:01
Abingdon Health Plc
Launch of seaweed-based lateral flow housings
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has launched seaweed-based lateral flow test (LFT) housings as a sustainable alternative to traditional plastic housings. This innovation aims to reduce the significant plastic waste generated by the over 2 billion LFTs used annually worldwide. The company has partnered exclusively with Symbio Technologies Ltd (SymbioTex) to supply compostable, bio-based material derived from red seaweed, which can be molded using standard injection techniques. Prototypes have been developed for both standard and mid-stream urine sample formats, including pregnancy tests. The seaweed-based housings maintain the functionality of traditional tests while offering an eco-friendly solution. This initiative aligns with Abingdon Health’s commitment to sustainability and leverages renewable resources without requiring new manufacturing infrastructure. The launch underscores the company’s role in addressing environmental concerns in the med-tech industry.
Litigation 0
No items for this category on selected date.
NewContract 1
ABDX 06:01
Abingdon Health Plc
c.US$2m multiplex diagnostic test contract win
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has secured a **c.US$2 million contract** with a US-based company for the development, scale-up, and technical transfer of a **semi-quantitative, multiplex lateral flow test system**. The 24-month project will be executed under a Master Service Agreement (MSA) and conducted at Abingdon Health’s Madison, Wisconsin facilities. This win highlights the strength of Abingdon Health’s **Contract Development and Manufacturing Organisation (CDMO)** services, which support customers from concept to commercial success. The contract underscores the company’s expanded U.S. manufacturing capabilities, bolstered by a recent £3.2 million fundraise, and its ability to meet growing demand from U.S.-based clients. Dr. Chris Hand, Executive Chairman, emphasized the value of Abingdon’s dual U.S. and U.K. sites and the versatility of lateral flow technology in measuring multiple analytes semi-quantitatively. The announcement reinforces Abingdon Health’s position as a comprehensive CDMO provider in the med-tech sector.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
ABDX 13:01
Abingdon Health Plc
Notice of AGM & Publication of 2025 Annual Report
Results 1
ABDX 06:01
Abingdon Health Plc
Final Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Abingdon Health PLCs Final Results for FY25**
**Overview**
Abingdon Health PLC, a leading developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech, announced its final results for the financial year ended 30 June 2025 (FY25). The company reported significant commercial and operational growth, driven by expanded contract development and manufacturing (CDMO) activities, strategic acquisitions, and geographic expansion.
**Commercial and Operational Highlights**
**CDMO Growth**Secured several large contracts, including
US$2m for sexually transmitted disease tests.
£800,000 UKRI funding for malaria rapid diagnostic tests.
Strategic partnerships with Okos Diagnostics for avian flu tests.
€2m CDMO contract for companion diagnostics with a European biotech firm.
Post-period contracts totaling ~US$4.5m for companion diagnostics and multiplex lateral flow tests.
**Expansion Initiatives**
Acquired CS Lifesciences (regulatory services) for £3.2m in August 2024.
Opened Abingdon Analytical Ltd (analytical services) in Doncaster and a US CDMO site in Madison, Wisconsin.
**Sustainability**Launched seaweed-based lateral flow housings to reduce plastic waste.
**Financial Performance**
**Revenue**£8.6m (FY25) vs. £6.1m (FY24), a 40% increase. Includes £0.16m UKRI grant-funded revenue.
**H2 FY25 Strength**Revenue of £5.5m (vs. £3.7m in H2 FY24) and improved adjusted EBITDA loss of £0.7m (vs. £0.2m loss in H2 FY24).
**Adjusted EBITDA Loss**£2.7m (FY25) vs. £1.2m (FY24), due to growth investments.
**Reported Operating Loss**£3.5m (FY25) vs. £1.4m (FY24), after depreciation, amortization, and one-off items.
**Cash Position**£1.9m at 30 June 2025, supported by £5.2m net proceeds from August 2024 fundraising and £3.2m post-period fundraising.
**Strategic Acquisitions and Integration**
CS Lifesciences acquisition deepened regulatory expertise and expanded into medical devices and software.
Integration progressing well, with a £500k+ contract win extended to over £1m.
**Geographic Expansion**
US CDMO site in Madison operational since April 2025, securing US$2m+ contracts.
Plans to expand US manufacturing capacity post-October 2025 fundraising.
**Product and Technology Development**
Launched seaweed-based lateral flow housings for sustainability.
Patented AI-driven AppDx® technology for commercial use.
**Outlook**
FY26 started strongly, with Q1 revenue significantly ahead of prior period.
Focus on revenue growth, cost control, and progression toward profitability and cashflow positivity by 2026.
Continued expansion in the US and execution of larger contracts.
**Leadership and Governance**
Appointed Tom Hayes as CFO in January 2025 and Dr. Katie Brenner as Non-Executive Director in April 2025.
Chris Hand continues as Executive Chairman, and Chris Yates focuses on commercial growth as President of Abingdon Health USA Inc.
**Conclusion**
Abingdon Health demonstrated robust growth in FY25, driven by strategic acquisitions, CDMO expansion, and geographic diversification. Despite increased investment-related losses, the company is well-positioned for FY26, with a strong pipeline and focus on profitability and cashflow improvement.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 3
ABDX 14:09
Abingdon Health Plc
Holding(s) in Company
ABDX 15:59
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
ABDX 06:01
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 8
ABDX 06:01
Abingdon Health Plc
Vesting and Award of Options under LTIP
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
ABDX 14:09
Abingdon Health Plc
Holding(s) in Company
ABDX 13:01
Abingdon Health Plc
Notice of AGM & Publication of 2025 Annual Report
ABDX 06:01
Abingdon Health Plc
Final Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Abingdon Health PLCs Final Results for FY25**
**Overview**
Abingdon Health PLC, a leading developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech, announced its final results for the financial year ended 30 June 2025 (FY25). The company reported significant commercial and operational growth, driven by expanded contract development and manufacturing (CDMO) activities, strategic acquisitions, and geographic expansion.
**Commercial and Operational Highlights**
**CDMO Growth**Secured several large contracts, including
US$2m for sexually transmitted disease tests.
£800,000 UKRI funding for malaria rapid diagnostic tests.
Strategic partnerships with Okos Diagnostics for avian flu tests.
€2m CDMO contract for companion diagnostics with a European biotech firm.
Post-period contracts totaling ~US$4.5m for companion diagnostics and multiplex lateral flow tests.
**Expansion Initiatives**
Acquired CS Lifesciences (regulatory services) for £3.2m in August 2024.
Opened Abingdon Analytical Ltd (analytical services) in Doncaster and a US CDMO site in Madison, Wisconsin.
**Sustainability**Launched seaweed-based lateral flow housings to reduce plastic waste.
**Financial Performance**
**Revenue**£8.6m (FY25) vs. £6.1m (FY24), a 40% increase. Includes £0.16m UKRI grant-funded revenue.
**H2 FY25 Strength**Revenue of £5.5m (vs. £3.7m in H2 FY24) and improved adjusted EBITDA loss of £0.7m (vs. £0.2m loss in H2 FY24).
**Adjusted EBITDA Loss**£2.7m (FY25) vs. £1.2m (FY24), due to growth investments.
**Reported Operating Loss**£3.5m (FY25) vs. £1.4m (FY24), after depreciation, amortization, and one-off items.
**Cash Position**£1.9m at 30 June 2025, supported by £5.2m net proceeds from August 2024 fundraising and £3.2m post-period fundraising.
**Strategic Acquisitions and Integration**
CS Lifesciences acquisition deepened regulatory expertise and expanded into medical devices and software.
Integration progressing well, with a £500k+ contract win extended to over £1m.
**Geographic Expansion**
US CDMO site in Madison operational since April 2025, securing US$2m+ contracts.
Plans to expand US manufacturing capacity post-October 2025 fundraising.
**Product and Technology Development**
Launched seaweed-based lateral flow housings for sustainability.
Patented AI-driven AppDx® technology for commercial use.
**Outlook**
FY26 started strongly, with Q1 revenue significantly ahead of prior period.
Focus on revenue growth, cost control, and progression toward profitability and cashflow positivity by 2026.
Continued expansion in the US and execution of larger contracts.
**Leadership and Governance**
Appointed Tom Hayes as CFO in January 2025 and Dr. Katie Brenner as Non-Executive Director in April 2025.
Chris Hand continues as Executive Chairman, and Chris Yates focuses on commercial growth as President of Abingdon Health USA Inc.
**Conclusion**
Abingdon Health demonstrated robust growth in FY25, driven by strategic acquisitions, CDMO expansion, and geographic diversification. Despite increased investment-related losses, the company is well-positioned for FY26, with a strong pipeline and focus on profitability and cashflow improvement.
ABDX 06:01
Abingdon Health Plc
c.US$2m multiplex diagnostic test contract win
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has secured a **c.US$2 million contract** with a US-based company for the development, scale-up, and technical transfer of a **semi-quantitative, multiplex lateral flow test system**. The 24-month project will be executed under a Master Service Agreement (MSA) and conducted at Abingdon Health’s Madison, Wisconsin facilities. This win highlights the strength of Abingdon Health’s **Contract Development and Manufacturing Organisation (CDMO)** services, which support customers from concept to commercial success. The contract underscores the company’s expanded U.S. manufacturing capabilities, bolstered by a recent £3.2 million fundraise, and its ability to meet growing demand from U.S.-based clients. Dr. Chris Hand, Executive Chairman, emphasized the value of Abingdon’s dual U.S. and U.K. sites and the versatility of lateral flow technology in measuring multiple analytes semi-quantitatively. The announcement reinforces Abingdon Health’s position as a comprehensive CDMO provider in the med-tech sector.
ABDX 06:01
Abingdon Health Plc
Launch of seaweed-based lateral flow housings
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has launched seaweed-based lateral flow test (LFT) housings as a sustainable alternative to traditional plastic housings. This innovation aims to reduce the significant plastic waste generated by the over 2 billion LFTs used annually worldwide. The company has partnered exclusively with Symbio Technologies Ltd (SymbioTex) to supply compostable, bio-based material derived from red seaweed, which can be molded using standard injection techniques. Prototypes have been developed for both standard and mid-stream urine sample formats, including pregnancy tests. The seaweed-based housings maintain the functionality of traditional tests while offering an eco-friendly solution. This initiative aligns with Abingdon Health’s commitment to sustainability and leverages renewable resources without requiring new manufacturing infrastructure. The launch underscores the company’s role in addressing environmental concerns in the med-tech industry.
ABDX 15:59
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
ABDX 06:01
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy

AI Crunch

Single-Ticker AI Crunch
ABDX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Abingdon Health Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ABDX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for ABDX on 2025-12-04.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
21781004
Enterprise Value
4187469
Public Float
66.76
Broker Target
19
Shares Out
251077850
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLF79J41
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
-890000.0
Cash
1918000.0
EPS
-0.01
Net Income
-3415000.0
Revenue
8429000.0
Enterprise Value
4187469
Trailing PE
-
Forward PE
53.1915
Price Sales TTM
2.2755
Price Book MRQ
3.1878
EV Revenue
1.8102
EV EBITDA
-0.2499

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
44.9753
Institutions As Of
2025-11-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit ABDX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-12-04 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Abingdon Health Plc has fresh news flow feeding the chart narrative.
AI Charts Studio
ABDX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-12-04 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -2.22%
RSI Gauge
Price Change
AI Forecast